Using GI-specific patient outcome measures in renal transplant patients: Validation of the GSRS and GIQLI

Quality of Life Research

Volumn 15, Issue 7, 2006, Pages 1223-1232

  Kleinman, Leah ^a   Kilburg, Anne ^b   Machnicki, Gerardo ^b   Faull, Randall ^c   Walker, Rowan ^d   Prasad, Ramesh ^e   Ambuehl, Patrice ^f   Bahner, Udo ^g   Margolis, Mary Kay ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

GIQLI; GSRS; Post renal transplant; Psychometrics

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL QUALITY OF LIFE INDEX; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RELIABILITY; TREATMENT OUTCOME; VALIDATION PROCESS; VOMITING;

ADULT; CROSS-SECTIONAL STUDIES; DEVELOPED COUNTRIES; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE;

EID: 33750587517     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-006-0053-5     Document Type: Article

References (34)

1. Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1990-1999. 2000.
2. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342(9): 605-612.
3. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63(7): 977-983.
4. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69(11): 2405-2409.
5. Helderman JH, Bennett WM, Cibrik DM, et al. Immunosuppression: Practice and trends. Am J Transplant 2003; 3(Suppl 4): 41-52.
6. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345(8961): 1321-1325.
7. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65(11): 1450-1454.
8. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/ MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69(5): 875-880.
9. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60(3): 225-232.
10. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation Apr 15 1996; 61(7): 1029-1037.
11. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol Sep 2003; 14(9): 2381-2386.
12. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant Jun 2003; 17(3): 200-205.
13. Ferguson RM, et al. The cost of mycophenolate mofetil (MMF)-related gastrointestinal adverse events and impact of MMF dose reductions/ discontinuations on acute rejection in transplanted patients. Poster presented at the Annual Meeting of the European Society for Organ Transplantation, Venice, September 20-24, 2003.
14. Hardinger KL, Brennan DC, Schnitzler MA. MMF Dose Modification Following Gastrointestinal Complications in Renal Transplantation. Boston: Poster presentation at the American Transplant Congress (ATC), 2004.
15. Hardinger KL, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int. 2004; 17: 609-616.
16. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. Br J Surg Feb 1995; 82(2): 216-222.
17. Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res Jan 1998; 7(1): 75-83.
18. Talley NJ, Fullerton S, Junghard O, et al. Quality of life in patients with endoscopy-negative heartburn: Reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96(7): 1998-2004.
19. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol Aug 1993; 28(8): 681-687.
20. Dimenas E, Glise H, Hallerback B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol Nov 1995; 30(11): 1046-1052.
21. Glise H, Hallerback B, Johansson B. Quality of Life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl 1995; 208: 133-135.
22. Eypasch E. Application of the Gastrointestinal Quality of Life Index (GIQLI): Data Collection, Storage and Graphical Display by a Computer Programme User Manual, English Version, November 1998. Available at: http:// www.qolid.org/member/giqli/cadre/manual-english.htm. Accessed, 2003.
23. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20(7): 455-462.
24. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy Dec 1990; 16(3): 199-208.
25. EuroQol Group. EQ-5D User Guide: A measure of health-related quality of life developed by the EuroQol Group. 1996, unpublished.
26. Kind P. The EuroQol Instrument: An index of health-related quality of life. In: Spilker B (ed.), Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996: 191-201.
27. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CD (eds.), et al. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Washington, DC: Le Jacq Publishing, 1984: 170-183.
28. MAPI Research Institute. Scaling and Scoring of the Psychological General Well-Being Index. Available at: http://www.qolid.org/member/giqli/cadre/manual- english.htm. Accessed, 2003.
29. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: Attributes and review criteria. Qual. Life Res. 2002; 11: 193-205.
30. Streiner DL, Norman GL. Health Measurement Scales: A practical guide to their development and use., 2nd ed., New York: Oxford University Press, 1995.
31. Nunnally JC, Bernstein IH. Psychometric Theory., 3rd ed., New York: McGraw-Hill, 1994.
32. Jenney ME, Campbell S. Measuring quality of life. Arch Dis Child Oct 1997; 77(4): 347-350.
33. McDowell I, Newell C. Measuring Health: A Guide to Rating Scale and Questionnaires., 2nd ed., New York, NY: Oxford University Press, 1996.
34. McColl E, Junghard O, Wiklund I, et al. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients. Am J Gastroenterol Jan 2005; 100(1): 11-18.